VANCOUVER, Feb. 27 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) announced
today that Dr. Peter Hnik, iCo's Chief Medical Officer, has been invited to
give a presentation discussing iCo-007 at the 7th International Symposium on
Ocular Pharmacology and Therapeutics (ISOPT) in Budapest, Hungary
(http://www.kenes.com/isopt/). Dr. Hnik's presentation, entitled, "iCo-007, a
VEGF "+" Agent, for the Potential Treatment of Diabetic Macular Edema and
Diabetic Retinopathy", will take place on March 2nd, 2008.
Designed and discovered by ISIS Pharmaceuticals, iCo-007 is a
second-generation antisense inhibitor targeting c-Raf kinase mRNA for the
treatment of Diabetic Macular Edema (DME) and Diabetic Retinopathy. iCo
licensed the worldwide exclusive rights to all therapeutic applications of
iCo-007 from ISIS in 2005.
"The invitation to such an influential conference is not only a
validation of iCo-007 and its clinical progress, but shows the value of a key
opinion leader group and CMO with expertise in ophthalmology", said Andrew
Rae, iCo's President & CEO.
iCo-007 is expected to decrease swelling in the retina and related visual
impairment by decreasing the signaling of multiple growth factors, including
VEGF, IGF, bFGF, EPO and HGF that signal through the c-Raf kinase / MAP kinase
pathway. iCo-007 is currently in a open label, dose escalating Phase I
clinical trial in DME patients. The primary endpoint of the trial is safety,
with visual acuity and measures of retinal thickness serving as secondary
iCo-007 may also be a potential treatment for certain oncology
indications, as c-Raf kinase is the predominant Raf isoform responsible for
regulating cellular growth in ovarian cancer.
About Diabetic Macular Edema
There are currently no approved therapeutics for DME, the leading cause
of blindness in working age adults. DME currently affects about 1.6 million
people in the U.S. alone, a number that is expected to grow as Diabetes is
forecast to increase by almost 50% in the US by 2025.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on
redosing or reformulating drugs with clinical history for new or expanded
indications. iCo has exclusive worldwide rights to two products, iCo-007, in
Phase I for the treatment of Diabetic Macular Edema, and iCo-008, a product
with Phase II clinical history to be developed for severe ocular allergies.
iCo Therapeutics also has an exclusive option to license iCo-009, a oral
reformulation of Amphotericin B for sight and life - threatening diseases.
iCo-009 also represents a new drug delivery technology with the potential to
reprofile other IV administered drugs to the oral route of administration.
iCo Therapeutics trades on the TSX-Venture exchange under the symbol
For more information, visit the company website at:
No regulatory authority has approved or disapproved the content of this
release. The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on iCo
Therapeutics' current beliefs as well as assumptions made by and information
currently available to iCo Therapeutics and relate to, among other things,
anticipated financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo Therapeutics in its
public securities filings; actual events may differ materially from current
expectations. iCo Therapeutics disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
For further information: Business Development Contact: Dr. John Clement,
CT&DO, (778) 688-0644; Finance Contact: Mr. John Meekison, CFO, (604) 602-9414
x 224; Investor/Media Contact: Frederica Bell, Corporate Development, (604)
602-9414 x 228